

Our pipeline

Project	Description	Indications	Partners	Pre-clinical	Phase 1	Phase 2	Phase 3	Filing	Regions
Delgocitinib¹	Topical pan-JAK inhibitor	Chronic Hand Eczema	 SHIONOGI	<div style="width: 100%;"></div>	Global				
		Chronic Hand Eczema (adolescents)		<div style="width: 100%;"></div>	Global				
		Lichen Sclerosus		<div style="width: 100%;"></div>	Global				
		Palmoplantar Pustulosis		<div style="width: 100%;"></div>	Global				
Tralokinumab²	Anti-IL-13 monoclonal antibody	Atopic Dermatitis (Pediatrics)	 AstraZeneca	<div style="width: 100%;"></div>	Global				
Spesolimab³	Anti-IL-36 R Monoclonal antibody	Pyoderma Gangrenosum	 Boehringer Ingelheim	<div style="width: 100%;"></div>	Global				
Calcipotriol and betamethasone dipropionate⁴	Fixed-Dose Combination	Plaque Psoriasis		<div style="width: 100%;"></div>	China ²				
Temptokibart	Anti-IL-22RA1 monoclonal antibody	Atopic Dermatitis	 argenx	<div style="width: 100%;"></div>	<div style="width: 100%;"></div>	<div style="width: 100%;"></div>			Global
IL-1RAcP	Anti-IL-1RAcP monoclonal antibody	Inflammatory skin diseases	 morphosys	<div style="width: 100%;"></div>	<div style="width: 100%;"></div>				Global
STAT6⁵	Oral program	Inflammatory skin diseases	 GILEAD	<div style="width: 100%;"></div>					Global
Topical STAT6⁶	Topical program	Inflammatory skin diseases		<div style="width: 100%;"></div>					Global



¹ Approved in the EU, US, UK, Australia, South Korea, Canada, Switzerland and the UAE for Chronic Hand Eczema

² Approved in the EU and U.S. and additional regions for atopic dermatitis.

³ Approved in the EU and U.S. and additional regions for Generalized Pustular Psoriasis. LEO Pharma in-licensed Spesolimab from Boehringer Ingelheim on September 30, 2025.

⁴ Approved in the EU and U.S. and additional regions for plaque psoriasis.

⁵ Partnership announced 11 January 2025: Gilead controls the global rights to oral STAT6 program and are in full control of the clinical development. LEO Pharma will have the option to co-commercialize oral programs for dermatology ex-US.

⁶ LEO Pharma holds an exclusive license from Gilead for STAT6 topical products in dermatology.